Correction of pressrelease: LIDDS announces preliminary outcome in the Rights Issue
The English pressrelease that was sent 6 February 2026 at 17.50 CET, which is a translation of the Swedish press release sent at the same time included an additional sentence by mistake. The following pressrelease is the correct version.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA, THE UNITED STATES OR ANY OTHER JURISDICTION, WHERE SUCH ACTIONS ARE SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER REGARDING ANY SECURITIES IN LIDDS AB. SEE ALSO THE “IMPORTANT INFORMATION” SECTION BELOW.
LIDDS AB (publ) (”LIDDS”or the ”Company”) today announces the preliminary outcome of the righs issue with preferential rights for the shareholders (the ”Rights Issue”), which subscription period ended today. The subscription breakdown shows that 24,967,268 shares, corresponding to 35.0 MSEK or approximately 71.9 percent of the Rights Issue, were subscribed for with or without the exercise of subscription rights. The Rights Issue was secured to approximately 95.7 percent through issue gurantees and the Company will therefore obtain approximately 46.5 MSEK before issue costs.
"I would like to thank all existing shareholders who have participated in the rights issue for your continued support and extend a warm welcome to new shareholders. The rights issue provides a significant reinforcement to the Company's continued development of Nanodotax and Nanoimod and enables intensified work with the out-licensing of the Phase III project Liproca® Depot", says Anders Månsson, CEO of LIDDS.
The subscription period in the Rights Issue ended today the 6 February 2023 and a preliminary breakdown shows that 24,967,268 shares, corresponding to 35.0 MSEK or approximately 71.9 percent of the Rights issue, were subscribed for with or without the exercise of subscription rights. The Rights Issue was secured to approximately 95.7 percent through issue guarantees and the Company will therefore obtain approximately 46.5 MSEK before issue costs.
The final outcome of the Rights Issue is expected to be announced on Wednesday 8 February 2023. Allocation of shares that were subscribed for without the exercise of subscription rights will be done according to the principles described in the prospectus that was prepared in connection with the Rights Issue and was published on 17 January 2023. Those who will be allocated shares without the support of subscription rights will be notified after the allocation meeting held by the Board of Directors on 8 February 2023 through contract note. Nominee shareholders will receive notification of allotment in accordance with the respective nominee's routines. Allocated shares should be paid according to the instructions on the contract note.
Erik Penser Bank AB is financial advisor to LIDDS in connection with the share issue and Setterwalls Advokatbyrå AB is legal advisor.
BBS-Bioactive Bone Substitutes Oyj:n varsinaisen yhtiökokouksen 2023 päätökset
BBS-Bioactive Bone Substitutes Oyj:n varsinainen yhtiökokous pidettiin torstaina 30.3.2023 alkaen kello 14.00 Oulussa.Yhtiökokous vahvisti yhtiön tilinpäätöksen tilikaudelta 2022 sekä myönsi vastuuvapauden hallituksen jäsenille ja toimitusjohtajalle.Yhtiökokous päätti hallituksen ehdotuksen mukaises...
BBS-Bioactive Bone Substitutes Plc: Decisions of the Annual General Meeting 2023
The maximum number of shares to be issued pursuant to the authorization shall not exceed 6,000,000 shares.The Board of Directors decides on all terms and conditions for issuing shares, options and other special rights entitling to shares. Share issues and the issuance of option rights and other spec...
Cyxone meddelar valberedningens förslag inför årsstämma samt två ledamöters utträde, och förändrade förutsättningar kring styrelsens beslutsmässighet
Cyxone (publ) meddelar att valberedningen för Cyxone AB presenterar sitt förslag till beslut på årsstämman avseende val av styrelseledamöter och styrelseordförande. Två ledamöter, Theresa Comiskey Olsen och Saad Gilani, har valt att avgå på egen begäran per den 31 mars. Denna förändring i styrelsens...
Resolutions of the Annual General Meeting of Curasight A/S
Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to i...